Based on the aggregated intelligence of 145,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, molecular diagnostic company Myriad Genetics (NASDAQ:MYGN) has earned a respected four-star ranking.

With that in mind, let's take a closer look at Myriad's business and see what CAPS investors are saying about the stock right now.

Myriad facts

Headquarters (Founded)

Salt Lake City (1991)

Market Cap

$2.4 billion

Industry

Biotechnology

Trailing-12-Month Revenue

$341.68 million

Management

CEO Dr. Peter Meldrum (since 1991)
CFO James Evans (since 2007)

Return on Equity (Average, Past 3 Years)

15.2%

Cash/Debt

$358 million / $0

Competitors

Abbott Labs (NYSE:ABT)
Hologic (NASDAQ:HOLX)

CAPS Members Bullish on MYGN Also Bullish on

Johnson & Johnson (NYSE:JNJ)
General Electric (NYSE:GE)

CAPS Members Bearish on MYGN Also Bearish on

Dendreon (NASDAQ:DNDN)
Amgen (NASDAQ:AMGN)

Sources: Capital IQ (a division of Standard & Poor's), Yahoo! Finance, and Motley Fool CAPS.

On CAPS, 94% of the 455 members who have rated Myriad believe the stock will outperform the S&P 500 going forward. These bulls include FitzColinGerald and CAPS All-Star BetapegLLC, who is ranked in the top 15% of our community.

Last fall, FitzColinGerald kindly informed Fools that Myriad "is a healthcare company that specializes in the development and marketing of prognostic medicine products." Our CAPS member concludes: "These products are becoming increasingly important, as patients wish to assess their potential risks with certain diseases and treatments."

In a pitch from two months later, BetapegLLC elaborates on that bullish line of thinking. Here's an excerpt:

Myriad's products specialize in preventative medicine which is a field expected to grow enormously. Healthcare paradigms are shifting from reactionary to proactive which is an issue highlighted by healthcare reform initiatives in the United States. The Company sees itself as the vanguard of a new disease prevention paradigm. The small market status of preventative medicine should enable Myriad to find its niche in new genetic testing procedures which are expected to see rising demand in the coming decades.

What do you think about Myriad, or any other stock for that matter? If you want to retire rich, you need to put together the best portfolio you can. Owning exceptional stocks is a surefire way to secure your financial future, and on Motley Fool CAPS, thousands of investors are working every day to find them. CAPS is 100% free, so get started!  

Fool contributor Brian Pacampara owns no position in any of the companies mentioned. Johnson & Johnson is a Motley Fool Income Investor pick. The Fool's disclosure policy always gets a perfect score.